Recognition, treatment, and prevention of heparin-induced thrombocytopenia: Review and update

Thrombosis Research

Volumn 118, Issue 2, 2006, Pages 165-176

  Greinacher, Andreas ^a   Warkentin, Theodore E ^b  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Direct thrombin inhibitor; Heparin induced thrombocytopenia; PF4; Platelets; Unfractionated heparin

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; COUMARIN; DANAPAROID; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; THROMBIN INHIBITOR; VITAMIN K GROUP; WARFARIN;

ANAPHYLAXIS; ARTERY THROMBOSIS; BLEEDING; CHILL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; FEVER; FLUSHING; GANGRENE; HEMODYNAMIC MONITORING; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INJECTION SITE REACTION; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LIFE; LIMB AMPUTATION; MEDICAL SOCIETY; MICROTHROMBUS; PHYSICIAN; PRIORITY JOURNAL; PROTHROMBIN TIME; PUBLICATION; RECOGNITION; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SYSTEMIC DISEASE; THORAX PAIN; THREAT; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOSIS; VEIN THROMBOSIS;

ANTICOAGULANTS; ANTITHROMBINS; BLOOD PLATELETS; HEPARIN; HUMANS; PLATELET COUNT; PLATELET FACTOR 4; PRACTICE GUIDELINES; THROMBOCYTOPENIA;

EID: 33645718758     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.07.012     Document Type: Review

References (38)

1. Warkentin T.E., Levine M.N., Hirsh J., Horsewood P., Roberts R.S., Gent M., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332 (1995) 1330-1335
2. King D.J., and Kelton J.G. Heparin-associated thrombocytopenia. Ann Intern Med 100 (1984) 535-540
3. Girolami B., Prandoni P., Stefani P.M., Tanduo C., Sabbion P., Eichler P., et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 101 (2003) 2955-2959
4. Warkentin T.E., and Kelton J.G. A 14-year study of heparin-induced thrombocytopenia. Am J Med 101 (1996) 502-507
5. Warkentin T.E. Current agents for the treatment of patients with heparin-induced thrombocytopenia. Curr Opin Pulm Med 8 (2002) 405-412
6. Spinler S.A. Managing heparin-induced thrombocytopenia: preventing life- and limb-threatening thrombosis. Introduction. Am J Health-Syst Pharm 60 S5 (2003) S2-S4
7. Warkentin T.E. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol 35 S5 (1998) 9-16
8. Hirsh J., Heddle N., and Kelton J.G. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 164 (2004) 361-369
9. Warkentin T.E. Heparin-induced thrombocytopenia: pathogenesis, frequency, avoidance and management. Drug Safety 17 (1997) 325-341
10. Francis J.L., Palmer III G.J., Moroose R., and Drexler A. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg 75 (2003) 17-22
11. Warkentin T.E., and Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [review]. Chest 126 (2004) 311S-337S
12. Guyatt G., Schünemann H.J., Cook D., Jaeschke R., and Pauker S. Applying the grades of recommendation for antithrombotic and thrombolytic therapy: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(S) (2004) 179S-187S
13. Aster R.H. Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 332 (1995) 1374-1376
14. Spinler S.A., and Dager W. Overview of heparin-induced thrombocytopenia. Am J Health-Syst Pharm 60 S5 (2003) S5-S11
15. Warkentin T.E., and Kelton J.G. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344 (2001) 1286-1292
16. Warkentin T.E., and Kelton J.G. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 135 (2001) 502-506
17. Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients. Thromb Haemost in press.
18. Greinacher A, Eichler P, Lietz T, Warkentin TE. Replacement of unfractioned heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood in press.
19. Warkentin T.E. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 127 S2 (2005) 35S-45S
20. Greinacher A., Amiral J., Dummel V., Vissac A., Kiefel V., and Mueller-Eckhardt C. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 34 (1994) 381-385
21. Wallis D.E., Workman D.L., Lewis B.E., Steen L., Pifarre R., and Moran J.F. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 106 (1999) 629-635
22. Slaughter T.F., and Greenberg C.S. Heparin-associated thrombocytopenia and thrombosis: implications for perioperative management. Anesthesiology 87 (1997) 667-675
23. Kadidal V.V., Mayo D.J., and Horne M.K. Heparin-induced thrombocytopenia (HIT) due to heparin flushes: a report of three cases. J Intern Med 246 (1999) 325-329
24. Greinacher A., Eichler P., Lubenow N., Kwasny H., and Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 96 (2000) 846-851
25. Greinacher A., and Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin. Circulation 103 (2001) 1479-1484
26. Refludan [package insert]. Wayne, NJ: Berlex Laboratories; 2002.
27. Argatroban [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2003.
28. Greinacher A. Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy. Exp Rev Cardiovasc Ther 2 (2004) 89-106
29. Lewis B.E., et al., for the ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103 (2001) 1838-1843
30. Lewis B.E., Wallis D.E., Leya F., Hursting M.J., Kelton J.G., and for The Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 163 (2003) 1849-1856
31. Lubenow N., Eichler P., Lietz T., Farner B., and Greinacher A. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood 104 (2004) 3072-3077
32. In: Warkentin T.E., and Greinacher A. (Eds). Heparin-induced thrombocytopenia. 2nd ed. (2001), Marcel Dekker, Inc., New York, NY
33. Lubenow N, Eichler P, Greinacher A. Results of a large drug-monitoring program confirms the safety and efficacy of Refludan (lepirudin) in patients with immune-mediated heparin-induced thrombocytopenia (HIT) [abstract]. Blood 2002;100(pt 1):502a [Abstract 1955].
34. Gosselin R.C., King J.H., Janatpour K.A., Dager W.E., Larkin E.C., and Owings J.T. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. Ann Pharmacother 38 (2004) 1383-1388
35. Hafner G., Roser M., and Nauck M. Methods for the monitoring of direct thrombin inhibitors. Semin Thromb Hemost 28 (2002) 425-430
36. Greinacher A., Lubenow N., and Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 108 (2003) 2062-2065
37. Greinacher A., et al., and for the Heparin-Associated Thrombocytopenia Study (HAT) Investigators. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 100 (1999) 587-593
38. Gosselin R.C., Dager W.E., King J.H., Janatpour K.A., Mahackian K.A., Larkin E.C., et al. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am J Clin Pathol 121 (2004) 593-599